Abstract
Despite new therapeutic options, MM still remains incurable and clearly, novel modalities complementing or improving current treatment options are needed. In this context, our group, as well as others, have previously reported that Natural Killer (NK) cells may be a feasible treatment modality. However individual patient NK cell myeloma cell interactions vary among patients and it is unclear if these interactions predict response to complementary treatments. Thus, with this project, we aim to identify therapeutic targets via systematic screening of NK cell/tumor cell interactions by using genetically modified autologous NK cells.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call